Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy
Alnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP)
to-BBB Completes Management Team and Announces Company Name Change to BBB Therapeutics
Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
A roundup of investment news.
Focusing on stocks with the most visible cash flows has been a winning strategy, and this screen can find them.
Who's in front heading 'round the bend?
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
This screen finds stocks that would make it into Morningstar's Wide-Moat Focus strategy.